Conditional survival in multiple myeloma and impact of prognostic factors over time.

Autor: Abdallah NH; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Smith AN; Department of biostatistics, Mayo Clinic, Rochester, MN, USA., Geyer S; Department of biostatistics, Mayo Clinic, Rochester, MN, USA., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Greipp PT; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Baughn LB; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hwa YL; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2023 May 15; Vol. 13 (1), pp. 78. Date of Electronic Publication: 2023 May 15.
DOI: 10.1038/s41408-023-00852-4
Abstrakt: Overall survival estimates from diagnosis are valuable for guiding treatment, but do not consider the years already survived. Conditional survival (CS) provides dynamic survival predictions over time. This study was conducted to estimate CS at 1-8 years from diagnosis and the impact of baseline prognostic factors on CS in multiple myeloma (MM) patients. This is a retrospective study including 2556 MM patients diagnosed between 2004 and 2019. CS (t | s) was defined as the probability of surviving t years given survival of s years. Median age was 64 years. Median follow-up was 6.2 years and median overall survival from diagnosis was 7.5 years. The 5-year CS estimates at s = 0, 1, 2, 3, and 5 years were 0.64, 0.61, 0.61, 0.61, and 0.58, respectively. On multivariate analysis, age ≥ 65 and proteasome inhibitor+immunomodulatory-based induction were associated with decreased survival and increased survival, respectively, retained at 5 years. The adverse impact of 1q gain/amplification, high-risk IgH translocation, and ISS-3 was significant at 1 and 3 years but not 5 years. Chromosome 17 abnormality was associated with decreased survival only at 1 year. Among MM patients, 5-year CS was stable at 1-5 years from diagnosis. The prognostic impact of high-risk cytogenetic factors decreased with additional years survived.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: